JumpStart Ventures Invests $250,000 in Thermalin Diabetes Inc.
03/29/2010
"Over the next 20 years, worldwide insulin sales are expected to grow from $12 billion to $54 billion, JumpStart Ventures partner Ted Frank told Crain's Cleveland Business. "That growth, combined with the medical community's interest in insulin with higher performance, fewer side effects, and storage flexibility, position Thermalin's pipeline to be in high demand."
Thermalin will use the funds to validate its insulin analogs' characteristics, locate a manufacturer, and proceed in the investigational drug process with the FDA.
The company's products include a faster meal-time insulin that is expected to reduce long-term side effects. The insulin can also be stored at higher temperatures, which would make transport and delivery easier.
Most Read
-
-
Hot Jobs: Growing Industrial Sectors
Q4 2019
-
2019 Leading Metro Locations: Pacific and South-Atlantic Metros Dominate the List
Q4 2019
-
34th Annual Corporate Survey & the 16th Annual Consultants Survey
Q1 2020
-
A Site Selector’s Checklist for Locating in the U.S.
Location USA 2019
-
2019 Top States for Doing Business: Georgia Ranks #1 Sixth Year in a Row
Q3 2019
-
In Focus: Mitigating Risk with Aggressive Support in Economic Development
Q1 2020